- Main
Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy
- Lee, Jaecheol;
- Termglinchan, Vittavat;
- Diecke, Sebastian;
- Itzhaki, Ilanit;
- Lam, Chi Keung;
- Garg, Priyanka;
- Lau, Edward;
- Greenhaw, Matthew;
- Seeger, Timon;
- Wu, Haodi;
- Zhang, Joe Z;
- Chen, Xingqi;
- Gil, Isaac Perea;
- Ameen, Mohamed;
- Sallam, Karim;
- Rhee, June-Wha;
- Churko, Jared M;
- Chaudhary, Rinkal;
- Chour, Tony;
- Wang, Paul J;
- Snyder, Michael P;
- Chang, Howard Y;
- Karakikes, Ioannis;
- Wu, Joseph C
- et al.
Published Web Location
https://doi.org/10.1038/s41586-019-1406-xAbstract
Lamin A/C (LMNA) is one of the most frequently mutated genes associated with dilated cardiomyopathy (DCM). DCM related to mutations in LMNA is a common inherited cardiomyopathy that is associated with systolic dysfunction and cardiac arrhythmias. Here we modelled the LMNA-related DCM in vitro using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Electrophysiological studies showed that the mutant iPSC-CMs displayed aberrant calcium homeostasis that led to arrhythmias at the single-cell level. Mechanistically, we show that the platelet-derived growth factor (PDGF) signalling pathway is activated in mutant iPSC-CMs compared to isogenic control iPSC-CMs. Conversely, pharmacological and molecular inhibition of the PDGF signalling pathway ameliorated the arrhythmic phenotypes of mutant iPSC-CMs in vitro. Taken together, our findings suggest that the activation of the PDGF pathway contributes to the pathogenesis of LMNA-related DCM and point to PDGF receptor-β (PDGFRB) as a potential therapeutic target.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-